Bharat Parenterals Ltd
Bharat Parenterals Ltd Q3 FY26 Results & Presentation Highlights: Revenue ₹65.2 Cr, PAT ₹9.6 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Bharat Parenterals Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). - Q3 FY26 Standalone Revenue from Operations: ₹41.4 crore, down 39% YoY from ₹67.3 crore in Q3 FY25 (Page 5). - Innoxel revenue guidance for full year FY26: ₹60–65 crore, contingent on milestone timing (Page 34). - Varenyam Healthcare full-year revenue target for FY26: approx. EBITDA for Q3 FY26 (Consolidated): ₹1.8 crore, down 52% YoY from ₹3.7 crore in Q3 FY25; margin at 3% vs.
From Bharat Parenterals Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9).
- Q3 FY26 Standalone Revenue from Operations: ₹41.4 crore, down 39% YoY from ₹67.3 crore in Q3 FY25 (Page 5).
- Innoxel revenue guidance for full year FY26: ₹60–65 crore, contingent on milestone timing (Page 34).
- Varenyam Healthcare full-year revenue target for FY26: approx. ₹60 crore (Page 34).
- BPL Standalone Q4 FY26 revenue outlook: ₹50–55 crore, expecting sequential recovery but below earlier full-year FY26 guidance due to PO deferment (Page 34).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 19).
- Varenyam Bio Lifesciences: Capex ~₹30 crore till date; facility under construction with targeted operational readiness by FY27 (Page 19).
- Standalone (BPL): FY25 Capex ₹14+ crore (Page 18).
- Beta-Lactam Block upgrades: Civil and layout modifications completed to align with EU-GMP compliance; new water system installed (Page 6).
- General Injectable Vial Line upgraded to ORABS standards enhancing manufacturing efficiency (Page 6).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation reports a robust order book of ₹303 crore, expected to benefit FY27 significantly, particularly in the first half (Page 34).
- It does not provide specific figures for order inflow or pending orders beyond the ₹303 crore order book mention.
- Management notes a timing shift in institutional execution leading to a deferral of Purchase Orders (POs), impacting full-year FY26 revenue guidance but expects recovery in Q4FY26 (Page 34).
- No explicit numerical data on order inflows or pending orders is provided elsewhere in the presentation.
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Shree Ganesh Remedies Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank
- Anuh Pharma Ltd (Q3 FY26)
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw
- Themis Medicare Ltd (Q3 FY26)
90.13 Cr, a 3.9% decline year-on-year from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY26 investor presentation — and how it ranks a
- Kopran Ltd (Q3 FY26)
2,804 lakhs (~16.87% increase) . Key investor presentation takeaways from Kopran Ltd's Q3 FY26 investor presentation — and how it ranks against sector peers.
Frequently Asked Questions
What were Bharat Parenterals Ltd Q3 FY26 results?
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). - Q3 FY26 Standalone Revenue from Operations: ₹41.4 crore, down 39% YoY from ₹67.3 crore in Q3 FY25 (Page 5). - Innoxel revenue guidance for full year FY26: ₹60–65 crore, contingent on milestone timing (Page 34). - Varenyam Healthcare full-year revenue target for FY26: approx. EBITDA for Q3 FY26 (Consolidated): ₹1.8 crore, down 52% YoY from ₹3.7 crore in Q3 FY25; margin at 3% vs.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 19).
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.